A5074461963- Coronary Interventions and Diagnostics
- Acute Myocardial Infarction Research
- Antiplatelet Therapy and Cardiovascular Diseases
- Atrial Fibrillation Management and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Cardiac Imaging and Diagnostics
- Peripheral Artery Disease Management
- Cardiac Arrhythmias and Treatments
- Lipoproteins and Cardiovascular Health
- Cardiac Valve Diseases and Treatments
- Cardiac electrophysiology and arrhythmias
- Adipokines, Inflammation, and Metabolic Diseases
- Acute Ischemic Stroke Management
- Blood Pressure and Hypertension Studies
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cardiac Structural Anomalies and Repair
- Cardiovascular Syncope and Autonomic Disorders
- Signaling Pathways in Disease
- Cardiac and Coronary Surgery Techniques
- Renal and Vascular Pathologies
- Heart Failure Treatment and Management
- Pharmaceutical Economics and Policy
- Cerebrovascular and Carotid Artery Diseases
- Gastrointestinal Bleeding Diagnosis and Treatment
- Sodium Intake and Health
AnMed Health Medical Center
2020-2023
AnMed Health
2007-2021
Yale University
2021
Clemson University
2014
Prisma Health
2014
Cardiovascular Research Foundation
2009-2012
Columbia University Irving Medical Center
2009-2010
Anderson University - South Carolina
2008-2010
Sarah Cannon
2010
HCA Healthcare
2010
Current guidelines for patients with moderate- or high-risk acute coronary syndromes recommend an early invasive approach concomitant antithrombotic therapy, including aspirin, clopidogrel, unfractionated low-molecular-weight heparin, and glycoprotein IIb/IIIa inhibitors. We evaluated the role of thrombin-specific anticoagulation bivalirudin in such patients.We assigned 13,819 to one three regimens: heparin enoxaparin plus a inhibitor, alone. The primary end points were composite ischemia...
The intensity of antiplatelet therapy during percutaneous coronary intervention (PCI) is an important determinant PCI-related ischemic complications. Cangrelor a potent intravenous adenosine diphosphate (ADP)-receptor antagonist that acts rapidly and has quickly reversible effects.In double-blind, placebo-controlled trial, we randomly assigned 11,145 patients who were undergoing either urgent or elective PCI receiving guideline-recommended to receive bolus infusion cangrelor loading dose 600...
ContextIn patients with moderate- and high-risk acute coronary syndromes (ACS) who undergo an early, invasive treatment strategy, current guidelines recommend administration of platelet glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibitors, either upstream to all prior angiography or deferred for selective use in the catheterization laboratory just angioplasty. The preferred approach is undetermined.ObjectiveTo determine optimal strategy Gp inhibitors ACS undergoing strategy.DesignProspective,...
Renal denervation (RDN) reduces blood pressure (BP) in patients with uncontrolled hypertension the absence of antihypertensive medications.
ContextAt 30-day follow-up, patients with moderate- and high-risk acute coronary syndromes (ACS) undergoing early invasive treatment in the ACUITY trial bivalirudin monotherapy vs heparin plus glycoprotein (GP) IIb/IIIa inhibitors had noninferior rates of adverse ischemic events reduced major bleeding. Deferred upstream use GP for selective administration to percutaneous intervention (PCI) resulted a significant reduction bleeding, although small increase composite ischemia could not be...
The clinical and angiographic predictors of early (<30 days) stent thrombosis (ST) have not been reported in high-risk patients with acute coronary syndromes.Qualitative quantitative analyses were performed 3405 moderate- syndromes whom stents implanted the prospective randomized Acute Catheterization Urgent Intervention Triage Strategy (ACUITY) trial, including 3043 (89.4%) drug-eluting implanted. Within 30 days, definite or probable ST occurred 48 (1.4%). rates significantly different...
The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial demonstrated that bivalirudin monotherapy significantly reduces major bleeding compared with heparin (unfractionated or enoxaparin) plus a glycoprotein IIb/IIIa inhibitor in acute coronary syndromes. Whether vascular closure devices (VCD) impact these results is unknown. Therefore, this study sought to determine whether VCD access site (ASB) patients syndromes undergoing early invasive management by the femoral...
Background: Despite treatment guidance endorsing shortened dual antiplatelet therapy (DAPT) duration in high bleeding risk (HBR) patients after drug-eluting stents, limited evidence exists to support these recommendations. The present study was designed examine the safety and effectiveness of 1-month DAPT following percutaneous coronary intervention with zotarolimus-eluting stents HBR patients. Methods: Onyx ONE Clear a prospective, multicenter, nonrandomized evaluating followed by single...
The aim of this study was to explore the safety and efficacy a dedicated drug-eluting stent for treatment coronary lesions with very small reference vessel diameter (RVD).Smaller RVD is associated increased risk restenosis target lesion failure (TLF) after implantation.This prospective, single-arm, multicenter trial Resolute Onyx 2.0-mm zotarolimus-eluting stent. primary endpoint 12-month TLF, which compared pre-specified performance goal. Subjects stable or unstable angina ischemia, ≤27 mm...
Myocardial infarction (MI) after drug-eluting stent placement has been associated with an unfavorable late prognosis. Although the etiology of periprocedural MI is multifactorial, sidebranch occlusion may be important contributing factor. We sought to identify incidence during zotarolimus-eluting (ZES) and paclitaxel-eluting (PES) relate occurrence MI.Angiograms were reviewed from patients randomly assigned treatment a ZES (597 patients; 943 sidebranches) or PES (619 977 sidebranches)....
Background: The lack of a specific counteragent to bivalirudin may complicate the management patients with coronary artery (CA) perforation during percutaneous intervention (PCI). Aim: Assess outcomes CA from three PCI trials comparing intravenous provisional glycoprotein (GP) IIb/IIIa inhibition versus unfractionated heparin (UFH) plus GP IIb/IIIa. Methods: A pooled analysis treated in randomized including REPLACE‐2, ACUITY, and HORIZONS‐AMI. Results: Among total 12,921 patients, occurred...
Background: High bleeding risk (HBR) patients undergoing percutaneous coronary intervention have been widely excluded from randomized device registration trials. The LF study (LEADERS FREE) reported superior outcomes of HBR receiving 30-day dual antiplatelet therapy after with a polymer-free drug-coated stent (DCS). LFII was designed to assess the reproducibility and generalizability benefits DCS observed in inform US Food Drug Administration decision. Methods: single-arm using...
Accelerated endothelial healing after targeted antiproliferative drug delivery may limit the long-term inflammatory response of drug-eluting stents (DESs). The novel Supreme DES is designed to synchronize early within 4 6 weeks implantation, leaving behind a prohealing permanent base layer. Whether safe and effective in short term can improve clinical outcomes not known.In an international, 2:1 randomized, single-blind trial, we compared treatment with durable polymer everolimus-eluting...